[Quo vadis in vaccines: From the empirical approach to the new wave of technology].
| Autor: | Fernández-Prada M; Servicio de Medicina Preventiva y Salud Pública, Hospital Vital Álvarez Buylla, Mieres, España., López Trigo JA; Geriatría, Grupo de Vacunas de la Sociedad Española de Geriatría y Gerontología, Madrid, España., Bayas JM; Departamento Médico, GSK, Tres Cantos, Madrid, España., Cambronero MDR; Departamento Médico, GSK, Tres Cantos, Madrid, España. Electronic address: charo.m.cambronero-martinez@gsk.com. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Revista espanola de geriatria y gerontologia [Rev Esp Geriatr Gerontol] 2020 May - Jun; Vol. 55 (3), pp. 160-168. Date of Electronic Publication: 2020 Feb 01. |
| DOI: | 10.1016/j.regg.2019.09.001 |
| Abstrakt: | The development of vaccines is a multifactorial process that has evolved and expanded, particularly over the last decades. The search for immunogenic vaccines that are also acceptably safe and tolerable enacted continuous technological advances in this field. In this regard, the technology applied to vaccines can historically be divided into 3 approaches: the empirical approach, the modern approach, and the new technological wave. The empirical approach for vaccine development includes whole micro-organisms, attenuation, inactivation, cell cultures and sub-unit vaccines. The modern approach contributed to leaps and bounds to vaccine development using chemical conjugation, as well as recombinant protein DNA technology and reverse vaccinology. Lastly, the new technological wave includes, among others, bioconjugation, viral vectors, synthetic biology, self-amplification of messenger RNA, generalized modules for membrane antigens, structural vaccinology and the new adjuvants. (Copyright © 2019 SEGG. Publicado por Elsevier España, S.L.U. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|